For men with genuine testosterone deficiency, TRT isn't a performance choice — it's medicine. Bodies fall apart without it. Eyesight changes, joints and connective tissue degrade, sleep collapses, mood crumbles, libido vanishes, recovery stops. The side-effect conversation has crowded out the bigger truth: untreated low testosterone harms men, sometimes severely. Once that's clear, the side-effect picture is a fair one to map honestly. So we do that here.
Genuinely low testosterone — typically below 8–10 nmol/L on a morning serum total testosterone test, though symptoms can appear higher in some men — is a medical condition with real consequences. It is not vanity, and it is not optimisation theatre.
What men actually experience at clinical deficiency:
Energy and fatigue: Persistent exhaustion that sleep doesn't fix. Difficulty getting through normal days.
Connective tissue and joints: Tendons and ligaments don't heal. Old injuries flare up and refuse to settle. Muscle is lost despite training. Recovery from any physical stress slows or stops.
Vision and ocular health: Testosterone affects tear production via the meibomian glands. Severe deficiency can present with chronic dry eye, blurred vision, and ocular surface disease — symptoms that resolve with replacement.
Bone density: Testosterone is a primary regulator of bone mineral density in men. Long-term deficiency drives osteopenia and osteoporosis, with fracture risk to match.
Mood and cognition: Depression, anxiety, brain fog, loss of motivation. The neurological symptoms are real, well-documented and frequently misdiagnosed as primary mental-health conditions.
Sleep architecture: Reduced REM and deep sleep. Sleep that doesn't restore.
Libido and sexual function: Loss of morning erections, reduced spontaneous arousal, erectile changes.
Cardiovascular and metabolic: Insulin resistance increases, visceral fat accumulates, lipid profile worsens.
For men with genuine deficiency, replacing testosterone reverses much of this. Not all of it, not always quickly — but the data on properly-supervised TRT in hypogonadal men is, on balance, strongly positive. The 2023 TRAVERSE trial — the largest TRT RCT ever conducted, with around 5,200 men over multiple years — found no increase in major adverse cardiovascular events versus placebo. Earlier-generation fears about TRT and cardiovascular disease have not held up under proper trial scrutiny.
That doesn't mean TRT is risk-free or for everyone. It means the framing has to start with the right comparison: not TRT vs nothing, but TRT vs continuing untreated deficiency. For men in genuine deficiency, the latter has substantial harms of its own.
Well-managed TRT typically restores total testosterone to the upper-normal range, with stable trough levels avoiding the swings of older protocols. Within 4–12 weeks most men report improvements in energy, mood, libido, sleep, and recovery. Connective tissue takes longer — measurable improvements in tendon and bone health unfold over 6–18 months. Body composition shifts gradually toward more lean mass and less visceral fat, especially when paired with resistance training.
The reason side effects need an honest accounting is precisely because the benefits are substantial. If TRT didn't work, no one would care about the management trade-offs. Below is the actual side-effect map for properly-supervised TRT — what's real, what's manageable with monitoring, and what's myth.
Testosterone stimulates erythropoiesis — red blood cell production. This causes haematocrit to rise in most men on TRT. Haematocrit above 54% meaningfully increases blood viscosity and cardiovascular risk. Management is straightforward: dose reduction, switching to more frequent smaller injections, or therapeutic phlebotomy.
It is not a reason to avoid TRT — it is a reason to monitor it. The risk is near-zero for men whose haematocrit is checked regularly and managed appropriately.
TRT suppresses the HPT axis, reducing LH production and testicular stimulation. Without stimulation, testicular volume decreases over months to years. Gonadorelin or HCG used alongside TRT can substantially mitigate atrophy by maintaining testicular stimulation despite suppressed endogenous LH.
Most well-managed TRT protocols now include gonadorelin or HCG for this reason.
TRT suppresses spermatogenesis. Men on TRT who are not using fertility-preserving adjuncts will typically have significantly reduced sperm counts. This is not permanent in most cases — spermatogenesis typically recovers after stopping TRT, though the timeline varies.
Men who wish to have children while on TRT require specialist reproductive endocrinologist input. This is not a situation for self-management.
Testosterone aromatises to oestradiol. On TRT, oestradiol levels typically rise. High oestradiol causes water retention, mood changes and gynecomastia. This is real.
However, oestradiol is also essential for male bone density, cardiovascular health, libido and cognitive function. Many TRT patients are over-prescribed aromatase inhibitors, driving oestradiol too low and creating worse symptoms. The evidence increasingly supports treating clear clinical symptoms rather than chasing a number on a lab report.
Testosterone converts to DHT via 5-alpha reductase. DHT causes follicle miniaturisation in men with androgenic alopecia. TRT can accelerate hair loss in men who are genetically predisposed — but does not cause it in men who are not.
Finasteride can reduce DHT but is associated with post-finasteride syndrome in a subset of users — a serious consideration before use.
The 2023 TRAVERSE trial — the largest randomised controlled trial of TRT — found no significant increase in major adverse cardiovascular events in hypogonadal men treated with testosterone. The picture is nuanced: TRT treating a genuine deficiency appears to have a different risk profile than supraphysiological use.
Men with existing significant cardiovascular disease should have specialist cardiac input before starting TRT.
Prostate cancer: TRT does not cause prostate cancer. The saturation hypothesis has been largely abandoned in the literature.
Liver damage: Relevant to oral methylated testosterone (largely discontinued). Injectable and transdermal forms do not cause liver damage.
Aggression: Physiological replacement in genuinely hypogonadal men more commonly improves mood and reduces irritability — not the reverse.
The platform connection: BPC-157, GHK-Cu and the mitochondrial peptides documented on this platform are used by men on TRT to support tissue health during long-term therapy. The full TRT companion protocol is available to members.
We'll email you when we publish something new. Free, no account needed, unsubscribe anytime.
Full TRT blood work calendar, gonadorelin protocol and peptide companion guide — available to members.